Mario M. Soldevilla
Pamplona, NC 31008, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
Journal: Molecular therapy. Nucleic acids
Published: March 28, 2020
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 01, 2019
Aptamer-iRNAs as Therapeutics for Cancer Treatment.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 28, 2018
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 25, 2018
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors.
Journal: Oncoimmunology
Published: December 12, 2017
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).
Journal: PloS one
Published: July 14, 2017
In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding.
Journal: Molecular therapy. Nucleic acids
Published: April 08, 2016
Aptamers: A Feasible Technology in Cancer Immunotherapy.
Journal: Journal of immunology research
Published: March 31, 2016
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.
Journal: Biomaterials
Published: November 05, 2015
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.
Journal: Oncotarget
Published: September 16, 2015
Last Updated: 09/26/2026